Pam has over 40 years experience in anti-infective drug discovery and medicinal chemistry, from Pharma (GSK and legacy companies) to Biotech (Cantab Anti-infectives, Spero Therapeutics) encompassing a wide variety of bacterial targets in hit-to-lead through lead optimisation to candidate selection. At Cantab this led to the discovery of SPR-206 which has recently completed Phase 1 trials. Pam joined Centauri Therapeutics in 2022 and has since been enjoying the challenges of working in the immunology space as a new approach to tackling antibiotic-resistant infections.